Tags

Type your tag names separated by a space and hit enter

Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region.
J Epidemiol Glob Health. 2012 Mar; 2(1):23-30.JE

Abstract

Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at a "Meningococcal Leadership Forum" (MLF), which took place in May 2010 in Dubai. The participants of the conference discussed the importance of introducing the concept of conjugate vaccines - especially for children and adolescents - and elaborated a consensus recommendation to support healthcare professionals and decision makers with their expertise. In experts' opinion, conjugate vaccines are the best choice for the prevention of meningococcal disease caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate vaccines are registered and available in the Middle East region, they should replace plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccination schedules, including infant vaccination concomitantly with basic EPI vaccines when licensed.

Authors+Show Affiliations

King Saud University, Riyadh, Saudi Arabia. amshibl@ksu.edu.saNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Consensus Development Conference
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23856395

Citation

Shibl, Atef, et al. "Consensus Recommendation for Meningococcal Disease Prevention in Children and Adolescents in the Middle East Region." Journal of Epidemiology and Global Health, vol. 2, no. 1, 2012, pp. 23-30.
Shibl A, Tufenkeji H, Khalil M, et al. Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region. J Epidemiol Glob Health. 2012;2(1):23-30.
Shibl, A., Tufenkeji, H., Khalil, M., & Memish, Z. (2012). Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region. Journal of Epidemiology and Global Health, 2(1), 23-30. https://doi.org/10.1016/j.jegh.2012.02.002
Shibl A, et al. Consensus Recommendation for Meningococcal Disease Prevention in Children and Adolescents in the Middle East Region. J Epidemiol Glob Health. 2012;2(1):23-30. PubMed PMID: 23856395.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region. AU - Shibl,Atef, AU - Tufenkeji,Haysam, AU - Khalil,Mohamed, AU - Memish,Ziad, AU - ,, Y1 - 2012/03/28/ PY - 2011/10/21/received PY - 2012/01/31/revised PY - 2012/02/10/accepted PY - 2013/7/17/entrez PY - 2012/3/1/pubmed PY - 2014/6/20/medline KW - Conjugate KW - Consensus recommendation KW - Invasive meningococcal disease KW - Middle East countries KW - Vaccine SP - 23 EP - 30 JF - Journal of epidemiology and global health JO - J Epidemiol Glob Health VL - 2 IS - 1 N2 - Facing the availability of the new generation of quadrivalent meningococcal conjugate vaccines (Menveo®, Menactra® and others pending for license) and their recent implementation in Saudi Arabia, experts from 11 countries of the Middle East region met at a "Meningococcal Leadership Forum" (MLF), which took place in May 2010 in Dubai. The participants of the conference discussed the importance of introducing the concept of conjugate vaccines - especially for children and adolescents - and elaborated a consensus recommendation to support healthcare professionals and decision makers with their expertise. In experts' opinion, conjugate vaccines are the best choice for the prevention of meningococcal disease caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate vaccines are registered and available in the Middle East region, they should replace plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccination schedules, including infant vaccination concomitantly with basic EPI vaccines when licensed. SN - 2210-6014 UR - https://www.unboundmedicine.com/medline/citation/23856395/Consensus_recommendation_for_meningococcal_disease_prevention_in_children_and_adolescents_in_the_Middle_East_region_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2210-6006(12)00006-8 DB - PRIME DP - Unbound Medicine ER -